East Timor vs Trinidad and Tobago: Estimated antiretroviral therapy coverage among people living with HIV
East Timor
66.0%
in 2025
Trinidad and Tobago
66.0%
in 2025
East Timor rank
95th
Trinidad and Tobago rank
95th
Estimated antiretroviral therapy coverage among people living with HIV over time
- East Timor
- Trinidad and Tobago
How they compare
East Timor currently reports 66.0% against 66.0% in Trinidad and Tobago, a difference of 0.0%.
Across all 23 years both countries report, Trinidad and Tobago has been ahead every year.
East Timor ranks 95th and Trinidad and Tobago ranks 95th of 143 countries.
Trinidad and Tobago has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | East Timor | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.1% | 10.4% | 9.3% | Trinidad and Tobago |
| 2010s | 16.1% | 54.9% | 38.8% | Trinidad and Tobago |
| 2020s | 53.0% | 64.0% | 11.0% | Trinidad and Tobago |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher estimated antiretroviral therapy coverage among people living with hiv, East Timor or Trinidad and Tobago?
- East Timor, at 66.0% against 66.0% in Trinidad and Tobago as of 2025.
- What is the difference in estimated antiretroviral therapy coverage among people living with hiv between East Timor and Trinidad and Tobago?
- 0.0%, with East Timor ahead.
- How many years of comparable data are there for East Timor and Trinidad and Tobago?
- 23 years are reported by both, from 2000 to 2025.
- How do East Timor and Trinidad and Tobago rank globally for estimated antiretroviral therapy coverage among people living with hiv?
- East Timor ranks 95th and Trinidad and Tobago ranks 95th of 143 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Estimated antiretroviral therapy coverage among people living with HIV (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.